ENDRA Life Sciences Installs First TAEUS System in the UK
- None.
- None.
Insights
The installation of ENDRA's TAEUS liver system at King's College Hospital represents a significant advancement in the evaluation of liver health technology. The TAEUS system utilizes Thermo Acoustic Enhanced Ultrasound, which is a non-invasive technique designed to measure liver fat. This is particularly important as the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), is on the rise globally. The ability to accurately assess liver fat is crucial for early detection and management of these conditions.
Comparing the TAEUS system's accuracy to that of MRI, which is the current research standard, could have substantial implications. If TAEUS proves to be as accurate or more so, it could become a more cost-effective and accessible option for liver fat assessment. This would be a major breakthrough, as MRI is expensive and not as widely available. The potential for TAEUS to be used in mobile units could also address healthcare disparities by reaching high-risk communities that may not have easy access to hospital-based services.
From a market perspective, ENDRA Life Sciences Inc.'s collaboration with a prestigious NHS institution like King's College Hospital could be seen as a strategic move to gain credibility and exposure in the UK healthcare market. The NHS is one of the largest single-payer healthcare systems in the world and its adoption of new technologies can influence other markets.
Should the clinical study demonstrate positive outcomes and the technology be published in a peer-reviewed journal, it could lead to increased demand for ENDRA's TAEUS system, not only within the NHS but also internationally. The scalability of the TAEUS system for use in mobile health units suggests a versatile application that could appeal to a wide range of healthcare providers looking to expand their liver health services. This could result in a significant market opportunity for ENDRA, as healthcare systems worldwide are focusing more on preventative care and management of chronic diseases.
Investors will likely monitor the progress of the clinical study closely, as the results could impact ENDRA's financial prospects. A successful study outcome could lead to broader adoption of the TAEUS system, potentially increasing ENDRA's revenue streams. Moreover, the ability to penetrate the NHS could serve as a strong endorsement to other health services globally, potentially opening up new markets.
However, investors should also consider the risks involved. The technology's market adoption will depend not only on the accuracy of the TAEUS system but also on factors such as cost, ease of use and integration into existing healthcare workflows. Furthermore, the competitive landscape, including other non-invasive liver assessment technologies, could influence ENDRA's market position. A critical factor will be how the TAEUS system differentiates itself from existing alternatives and whether it can demonstrate clear advantages.
King's College Hospital in London Leads
KCH will use ENDRA's TAEUS liver system in a clinical study to compare its liver fat assessment accuracy with MRI, the acknowledged research standard. This study is expected to include approximately 75 subjects, and is intended to provide essential data to evaluate the TAEUS technology's performance. In addition, the findings of the study are expected to be submitted for publication in a peer-reviewed medical journal.
“We’re proud to launch our partnership with one of the
"We're looking forward to working with ENDRA and the TAEUS technology," stated Dr. Ashley Barnabas, Hepatologist in the Liver Unit at King’s College Hospital NHS Foundation Trust. “The NHS operates more than 900 hospitals, serves 1.3 million people daily and is increasingly focusing on liver health. This includes innovative mobile NHS units that provide liver health assessments in high-risk communities. ENDRA's versatile TAEUS system could potentially be suited for such outreach initiatives in the future."
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology, which characterizes tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including tissue temperature imaging during energy-based surgical procedures. For information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227291943/en/
Company:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com
Investor Relations:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: ENDRA Life Sciences Inc.
FAQ
What is the name of the company mentioned in the press release?
Where was the TAEUS liver system installed for a clinical study?
What is the ticker symbol of ENDRA Life Sciences Inc.?
How many subjects are expected to be included in the study at KCH?
What is the purpose of the clinical study at KCH?
